Zacks Research Issues Optimistic Estimate for TBPH Earnings

Theravance Biopharma, Inc. (NASDAQ:TBPH) – Investment analysts at Zacks Research upped their Q2 2026 earnings per share (EPS) estimates for shares of Theravance Biopharma in a report issued on Monday, January 13th. Zacks Research analyst R. Department now expects that the biopharmaceutical company will post earnings of ($0.11) per share for the quarter, up from their prior estimate of ($0.12). The consensus estimate for Theravance Biopharma’s current full-year earnings is ($1.09) per share.

Theravance Biopharma Price Performance

Shares of NASDAQ TBPH opened at $8.61 on Thursday. The firm’s 50-day moving average price is $9.48 and its two-hundred day moving average price is $8.90. Theravance Biopharma has a 52-week low of $7.44 and a 52-week high of $10.44.

Theravance Biopharma (NASDAQ:TBPH) last released its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.16). Theravance Biopharma had a negative return on equity of 24.79% and a negative net margin of 78.18%. The business had revenue of $16.87 million during the quarter, compared to analyst estimates of $16.11 million. During the same period in the prior year, the firm earned ($0.17) EPS.

Insider Buying and Selling

In related news, SVP Rhonda Farnum sold 4,000 shares of the stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $9.00, for a total value of $36,000.00. Following the sale, the senior vice president now owns 322,743 shares of the company’s stock, valued at $2,904,687. This trade represents a 1.22 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 6.90% of the company’s stock.

Institutional Investors Weigh In On Theravance Biopharma

Several large investors have recently made changes to their positions in TBPH. Barclays PLC grew its holdings in Theravance Biopharma by 279.9% in the 3rd quarter. Barclays PLC now owns 65,580 shares of the biopharmaceutical company’s stock worth $529,000 after buying an additional 48,316 shares in the last quarter. Squarepoint Ops LLC acquired a new position in Theravance Biopharma during the 2nd quarter worth $986,000. Bank of Montreal Can grew its stake in shares of Theravance Biopharma by 141.0% in the second quarter. Bank of Montreal Can now owns 160,138 shares of the biopharmaceutical company’s stock worth $1,414,000 after purchasing an additional 93,702 shares in the last quarter. Algert Global LLC bought a new position in shares of Theravance Biopharma in the third quarter worth $851,000. Finally, Dimensional Fund Advisors LP increased its holdings in shares of Theravance Biopharma by 38.4% during the second quarter. Dimensional Fund Advisors LP now owns 330,181 shares of the biopharmaceutical company’s stock valued at $2,800,000 after purchasing an additional 91,679 shares during the period. Institutional investors and hedge funds own 99.10% of the company’s stock.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.